Related Experiment Video

Updated: Aug 15, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and

J Ingles, A Doolan, C Chiu

    Journal of Medical Genetics
    |October 4, 2005
    PubMed

    Insights

    Multiple gene mutations in hypertrophic cardiomyopathy (HCM) patients are linked to a more severe clinical outcome. Comprehensive genetic screening is crucial for accurate diagnosis and risk assessment in HCM families.

    Area of Science:

    • Cardiovascular Genetics
    • Molecular Cardiology
    • Genetic Epidemiology

    Background:

    • Hypertrophic cardiomyopathy (HCM) is a primary genetic heart muscle disease.
    • Genetic mutations are the primary cause of HCM.
    • Identifying causative mutations aids in diagnosis and risk stratification.

    Discussion:

    • Multiple gene mutations in HCM families may lead to a more severe clinical phenotype.
    • A "double dose" effect from multiple mutations could exacerbate disease severity.
    • Sudden cardiac death events were more frequent in individuals with multiple mutations.

    Key Insights:

    • 29% of Australian HCM patients screened had identified mutations.
    • Multiple gene mutations were found in 5% of probands.
    • Compound mutations correlated with increased septal wall thickness.

    Outlook:

    • Screening the entire panel of HCM genes is essential, even after identifying a single mutation.
    • Further research into the "double dose" effect is warranted.
    • Genetic testing can improve personalized risk assessment and management strategies for HCM.
    Abstract

    More Related Videos

    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

    Published on: November 2, 2020

    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

    Published on: January 16, 2019

    Related Concept Videos

    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Mutations01:39

    Mutations

    Overview
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy I: Introduction and Classification01:25

    Cardiomyopathy I: Introduction and Classification

    Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...